Spots Global Cancer Trial Database for standard therapy
Every month we try and update this database with for standard therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast | NCT03047889 | Advanced Breast... | standard therap... | 18 Years - 99 Years | ChineseAMS | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer | NCT00003674 | Breast Cancer Colorectal Canc... Lung Cancer Prostate Cancer Veno-occlusive ... | dalteparin standard therap... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Cilengitide Imaging Trial in Glioblastoma | NCT01558687 | Supratentorial ... | Drug (including... Standard therap... | 18 Years - 70 Years | Merck KGaA, Darmstadt, Germany | |
| Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer | NCT04070976 | Cervical Cancer | Hypofractionate... Standard therap... | 18 Years - | National Institute of Cancerología | |
| Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy | NCT02597075 | Metastatic Colo... | standard therap... standard therap... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. | NCT05016349 | Breast Cancer F... | All trans-retin... 13-Cis Retinoic... Mifepristone Cannabidiol 9 cis retinoic ... Tamoxifen Standard therap... | 18 Years - 70 Years | Kafrelsheikh University | |
| A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast | NCT03047889 | Advanced Breast... | standard therap... | 18 Years - 99 Years | ChineseAMS | |
| Radical Prostatectomy and Perioperative Fluid Therapy | NCT00771966 | Prostate Cancer | Standard therap... Maximization of... | 18 Years - 80 Years | Rigshospitalet, Denmark | |
| Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. | NCT05016349 | Breast Cancer F... | All trans-retin... 13-Cis Retinoic... Mifepristone Cannabidiol 9 cis retinoic ... Tamoxifen Standard therap... | 18 Years - 70 Years | Kafrelsheikh University | |
| Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients | NCT01129336 | First or Second... Metastatic Dise... | Zoledronic acid Standard Therap... | 18 Years - | Novartis | |
| Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism | NCT01220050 | Renal Transplan... Secondary Hyper... | Paricalcitol Standard therap... | 18 Years - 80 Years | Mario Negri Institute for Pharmacological Research | |
| Cilengitide Imaging Trial in Glioblastoma | NCT01558687 | Supratentorial ... | Drug (including... Standard therap... | 18 Years - 70 Years | Merck KGaA, Darmstadt, Germany | |
| Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism | NCT01220050 | Renal Transplan... Secondary Hyper... | Paricalcitol Standard therap... | 18 Years - 80 Years | Mario Negri Institute for Pharmacological Research | |
| Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients | NCT01129336 | First or Second... Metastatic Dise... | Zoledronic acid Standard Therap... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
